CN114145354B - Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof - Google Patents
Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof Download PDFInfo
- Publication number
- CN114145354B CN114145354B CN202111453114.8A CN202111453114A CN114145354B CN 114145354 B CN114145354 B CN 114145354B CN 202111453114 A CN202111453114 A CN 202111453114A CN 114145354 B CN114145354 B CN 114145354B
- Authority
- CN
- China
- Prior art keywords
- formula
- content
- lactose
- intestinal
- tetraose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
Abstract
The invention provides breast milk oligosaccharide-containing formula milk powder and a preparation method and application thereof. Specifically, the invention provides a formula milk powder, which contains breast milk oligosaccharide lactose-N-tetraose and 3'-sialyllactose, wherein the mass ratio of lactose-N-tetraose to 3' -sialyllactose is (3-5): 1 and the total content of lactose-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g based on the total mass of the formula. The invention also provides a preparation method of the formula milk powder and application of the formula milk powder.
Description
Technical Field
The invention relates to a formula milk powder containing breast milk oligosaccharide and a preparation method and application thereof, in particular to a formula milk powder containing lactose-N-tetraose and 3' -sialyllactose, a preparation method and related application thereof, and belongs to the technical field of formula milk powder.
Background
Intestinal leakage (leak gun) refers to the phenomenon in which an increase in intestinal permeability causes intestinal harmful substances such as bacteria and toxins to pass through the intestinal mucosa into other tissues, organs and blood circulation in the human body. Intestinal permeability is related to intestinal barrier function, and normal intestinal permeability depends on the integrity of the intestinal mucosal barrier. Intestinal mucosal barriers are a complex multi-layer system that includes physical barriers, chemical barriers, biological barriers, and immune barriers. The interaction of these barriers allows the intestinal tract to maintain a permeability balance, preventing the loss of water and electrolytes and the entry of antigens and microorganisms into the body, while allowing the exchange of molecules between the body and the environment and the absorption of nutrients in the food.
The physical barrier of the intestinal tract serves as a first line of defense against the external environment and occupies a central position in the structure of the intestinal tract, and is composed of intestinal epithelial cells and intercellular junctions. Intestinal cell permeability is largely divided into transepithelial or transcellular and paracellular. Paracellular permeability is dependent on transport through the interstitial space between cells. The intercellular junctions include tight junctions, adhesive junctions, desmosomes, etc., of which the most important is the tight junctions, which are located at the top of the outer membrane of the intestinal epithelium, are of a narrow band-like structure to block the intercellular spaces, thereby preventing macromolecular substances such as bacteria and toxins in the intestinal lumen from entering the blood circulation through the intercellular spaces. The tight junctions between cells have a high dynamic stability, and their permeability determines the barrier function of the whole intestinal epithelial cells, and are regulated by intracellular and extracellular signals, and can be affected by diet, diseases, stress, etc.
The intestinal chemical barrier is mainly composed of a mucus layer which alters the sites of intestinal microorganisms and prevents them from directly contacting the host intestinal tissue cells. In addition, some substances produced in the intestinal tract such as bile salts, mucopolysaccharides, lysozyme and glycoproteins may also act as a chemical barrier.
The intestinal biological barrier is a microecological system with dynamic stability formed by intestinal symbiotic bacteria and a host, the intestinal symbiotic bacteria are attached to a mucous membrane layer on the surface of the intestinal canal of the host, a microbial barrier formed by bacteria is formed, and the colonisation and the multiplication of pathogenic bacteria are inhibited through mechanisms such as competitive adhesion and the like.
In the intestinal tract immune barrier, the related lymphoid tissues of the intestinal tract play a role in playing a role in resisting pathogen invasion, wherein lymphocytes, macrophages and the like play a role in playing a role in resisting pathogen invasion, and in effector molecules of intestinal tract immunity, secretory immunoglobulin A (sIgA) plays a key role, is produced in the lamina propria of the intestinal tract and secreted into the intestinal cavity after being processed by intestinal epithelial cells, can block adhesion of antigens such as bacteria, toxins, viruses and the like on the mucous membrane, and plays a role in clearing the antigens.
Intestinal leakage from abnormal intestinal barrier function is a major potential cause of many health problems, including irritable bowel syndrome, headache, weight gain, hashimoto thyroiditis, anxiety, depression, autoimmune diseases and allergies, and the like. In particular, microbial toxins produced by the metabolism of the intestinal flora, or other toxin substances which enter with food, penetrate through the intestinal wall with increased permeability ("intestinal leakage") into the blood circulation, and cause various autoimmune symptoms or poison internal organs by stimulating the autoimmune system, thus causing various diseases.
Compared with infants fed by breast milk, infants not fed by breast milk are unsound in intestinal development, and intestinal leakage is easier to occur.
Thus, there is a need for a solution that can prevent the occurrence of intestinal leaks to promote intestinal health.
Disclosure of Invention
It is an object of the present invention to provide a formula.
The invention also aims at providing a preparation method of the formula milk powder.
It is a further object of the present invention to provide the use of said formula.
The inventor finds that the combination of breast milk oligosaccharide lactose-N-tetraose (LNT) and 3' -sialyllactose (3 ' -sialylactose, 3' -SL or 3 SL) according to a specific proportion can be used for preventing or improving intestinal leakage or intestinal barrier injury, is beneficial to improving intestinal permeability and intestinal barrier among cells and improving the gap among cells, and is particularly beneficial to maintaining the intestinal health of infants. Thus, the lactose-N-tetraose and 3' -sialyllactose are added into the milk powder in the invention, so that the formula milk powder capable of promoting intestinal health is provided.
lactose-N-tetraose is a representative substance of oligosaccharides based on core sugar chains and free of fucosyl or sialyl groups, which are generally commercially available as prepared by microbial fermentation and have the same structure as lactose-N-tetraose found in human milk.
3' -sialyllactose, which is a trisaccharide structure formed by sialic acid and lactose, is a representative substance of sialyl oligosaccharides. The 3'-sialyllactose commercial products in the prior art are mostly prepared by a microbial fermentation method, and have the same structure as the 3' -sialyllactose found in human milk.
Specifically, in one aspect, the invention provides a formula milk powder, which contains the breast milk oligosaccharide lactose-N-tetraose and 3'-sialyllactose, wherein the mass ratio of lactose-N-tetraose to 3' -sialyllactose is (3-5): 1 and the total content of lactose-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g based on the total mass of the formula.
According to a specific embodiment of the invention, the formula of the invention is a non-infant milk powder or an infant formula. Wherein the non-infant milk powder can be milk powder for children or milk powder for adults (including middle-aged and elderly people).
According to a specific embodiment of the invention, the total protein content of the formula is 10-20 g/100g based on the total mass of the formula; the fat content is 15-30 g/100g; the carbohydrate content is 50-70 g/100g.
According to the specific embodiment of the invention, the formula milk powder also contains linoleic acid and alpha-linolenic acid, and the content of the linoleic acid is 2700-4500 mg/100g and the content of the alpha-linolenic acid is 270-450 mg/100g based on the total mass of the formula milk powder.
According to a specific embodiment of the invention, the mass ratio of lactose-N-tetraose to 3' -sialyllactose in the formula of the invention is 4:1.
according to a specific embodiment of the present invention, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula is 18-2841mg/100g based on the total mass of the formula.
According to a specific embodiment of the present invention, the total content of lactose-N-tetraose in the formula is not less than 14.2mg/100g, preferably 14.2-2273.0mg/100g, based on the total mass of the formula. In some embodiments of the invention, the total content of lactose-N-tetraose in the formula is 70.9-1515.3mg/100g powder, preferably 70.9-757.7mg/100g, based on the total mass of the formula.
In addition, unless otherwise noted, the amounts of 3' -sialyllactose used in the formula of the present invention are all used with reference to the aforementioned ratios.
In some specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula of the present invention may be 2000-3000mg/100g. In some specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula of the present invention may be 500-1800mg/100g powder. In some specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula of the present invention may be 18-300mg/100g powder.
In some embodiments of the invention, the formula of the invention is a formula for infants from 0 to 6 months, wherein the total protein content is from 10 to 15g/100g, the fat content is from 23 to 30g/100g, the linoleic acid content is from 2700 to 4500mg/100g, the alpha-linolenic acid content is from 270 to 450mg/100g, and the carbohydrate content is from 50 to 60g/100g, based on the total mass of the formula. In some more specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula may be 2000-3000mg/100g powder, preferably 2200-2841mg/100g powder.
In some embodiments of the invention, the formula of the invention is a formula for older infants from 6 to 12 months, wherein the total protein content is 10 to 20g/100g, the fat content is 20 to 30g/100g, the linoleic acid content is 2700 to 4500mg/100g, the alpha-linolenic acid content is 270 to 450mg/100g, and the carbohydrate content is 50 to 65g/100g, based on the total mass of the formula. In some more specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula may be 500-1800mg/100g powder, e.g. 800-1500mg/100g powder, preferably 900-1200mg/100g powder.
In some embodiments of the invention, the formula of the invention is a formula for infants from 12 to 36 months, wherein the total protein content is 10 to 20g/100g, the fat content is 15 to 30g/100g, the linoleic acid content is 2700 to 4500mg/100g, the alpha-linolenic acid content is 270 to 450mg/100g, and the carbohydrate content is 50 to 70g/100g, based on the total mass of the formula. In some more specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula may be 18-300mg/100g powder, e.g. 50-200mg/100g powder, preferably 80-150mg/100g powder.
According to a specific embodiment of the present invention, in the formula of the present invention, the raw materials for providing total protein include: raw milk (cattle/sheep), whole milk powder (cattle/sheep), skimmed milk powder (cattle/sheep), whey protein powder (cattle/sheep), desalted whey powder (cattle/sheep), and beta-casein. Specifically, the formula milk powder comprises the following raw materials in parts by weight based on 1000 parts by weight: raw milk (cattle/sheep) 0-3500 parts, whole milk powder 0-260 parts (cattle/sheep), whey protein powder (cattle/sheep) 0-120 parts, skim milk powder (cattle/sheep) 0-400 parts, and/or desalted whey powder (cattle/sheep) 0-600 parts, with the addition of beta-casein being 0-40 parts.
According to a specific embodiment of the invention, the raw materials for providing fat in the formula milk powder comprise one or more of the following raw materials in parts by weight: 0-50 parts of corn oil, 0-65 parts of soybean oil, 0-100 parts of sunflower seed oil, 0-240 parts of 1, 3-dioleoyl-2-palmitic acid triglyceride, 0-30 parts of coconut oil, 0-85 parts of canola oil and 0-20 parts of linseed oil.
According to a specific embodiment of the present invention, in the formula of the present invention, the raw material for providing breast milk oligosaccharide is commercially available food grade breast milk oligosaccharide raw material.
According to a specific embodiment of the present invention, in the formula of the present invention, the carbohydrate-providing raw materials include: lactose 0-500 parts, and/or the above protein material containing lactose.
According to a specific embodiment of the present invention, the formula of the present invention, in particular the infant formula, may comprise, in addition to the above components, conventional components of the formula, for example for infant formulas, one or more of nutrients, dietary fibres, inositol, taurine, l-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin. Preferably comprising a reconstituted nutrient package. In some preferred embodiments, the infant formula comprises 0-20 parts of nutrients including vitamins and minerals, or further optionally one or more of dietary fiber (fructooligosaccharides, galactooligosaccharides, polyfructose, etc.), inositol, taurine, l-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin. The compound nutrient mainly comprises the following components: and (3) compounding vitamins: vitamin A, vitamin D, vitamin E, vitamin K 1 Vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Niacin, folic acid, pantothenic acid, vitamin C, choline, biotin; compounding minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium, and derivatives thereof. The sources, the contents and the usage amount of each vitamin and mineral substance should meet the national standard and related regulations of milk powder or infant formula food.
On the other hand, the invention also provides a method for preparing the formula milk powder, which adopts a wet or dry production process to mix the breast milk oligosaccharide lactose-N-tetrasugar and 3' -sialyllactose with other raw materials in the formula milk powder to prepare the formula milk powder. The preparation process mainly comprises the following steps: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain the finished product. In the invention, lactose-N-tetraose and 3' -sialyllactose can be mixed together during the mixing process, or can be added during the post-mixing or dry mixing process. The specific process conditions can be carried out by referring to conventional methods in the field of formula milk powder production.
On the other hand, the invention also provides application of the formula milk powder in preparing a product with the effect of preventing intestinal leakage. In other words, the present invention provides the use of a breast milk oligosaccharide composition comprising lactose-N-tetraose and 3' -sialyllactose in the preparation of a product having an intestinal leakage preventing effect.
According to a specific embodiment of the invention, the preventing intestinal leakage comprises improving intercellular intestinal permeability and/or intestinal barrier.
According to a specific embodiment of the invention, the preventing intestinal leakage comprises reducing intercellular spaces.
In combination, the present invention provides a formula containing lactose-N-tetraose and 3' -sialyllactose. The breast milk oligosaccharide composition comprising lactose-N-tetraose and 3' -sialyllactose can be used for preventing or improving intestinal leakage or intestinal barrier injury, is beneficial to improving intercellular intestinal permeability and intestinal barrier, improves intercellular clearance, and is particularly beneficial to maintaining intestinal health of infants.
Drawings
FIG. 1 shows the effect of breast milk oligosaccharide on the molecular transport of FD 4.
Detailed Description
In order to more clearly understand the technical features, objects and advantages of the present invention, the technical solutions of the present invention will now be described in detail with reference to specific examples, which should be understood to be only illustrative of the present invention and not limiting the scope of the present invention.
Unless specifically defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the relevant art.
In the examples, lactose-N-tetraose and 3'-sialyllactose were obtained from Jennewein, a supplier, and the content of lactose-N-tetraose and 3' -sialyllactose was measured by a method conventional in the art. The operating conditions not specified in detail in the examples were carried out according to the usual procedures in the art.
Example 1
The present example provides a powdered infant formula of 0 to 6 months of age having a total protein content of 10.5g/100g powder and a fat content of 27.9g/100g powder; a carbohydrate content of 53.5g/100g flour; the content of the breast milk oligosaccharide composition is 2.8g/100g powder.
The infant formula powder is prepared by compounding the following raw materials in parts by weight:
1300 parts of raw milk, 500 parts of desalted whey powder, 220 parts of mixed vegetable oil (containing OPO), 90 parts of lactose, 15 parts of skimmed milk powder, 5 parts of whey protein powder, 31 parts of breast milk oligosaccharide LNT and 3'-SL composition, wherein the mass ratio of LNT to 3' -SL is about 3:1, 2.5 parts of compound vitamin and 8 parts of compound mineral.
The infant formula of this embodiment is prepared by a dry process, and mainly comprises: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding breast milk oligosaccharide composition to obtain the final product.
Example 2
This example provides a powdered infant formula of 6 to 12 months of age having a total protein content of 12.0g/100g powder and a fat content of 23.3g/100g powder; a carbohydrate content of 54.6g/100g flour; the content of the breast milk oligosaccharide composition is 0.9g/100g powder.
The infant formula powder is prepared by compounding the following raw materials in parts by weight:
280 parts of desalted whey powder (source goat milk), 220 parts of whole goat milk powder, 155 parts of mixed vegetable oil (containing OPO structural fat), 100 parts of lactose, 210 parts of lactose, 40 parts of whey protein powder (source goat milk), 10 parts of breast milk oligosaccharide LNT and 3'-SL composition, wherein the mass ratio of LNT to 3' -SL is about 4:1, 3.5 parts of compound vitamin and 15 parts of compound mineral substance.
The infant formula of this embodiment is prepared by a dry process, and mainly comprises: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding breast milk oligosaccharide composition to obtain the final product.
Example 3
The embodiment provides a powdered formula goat milk powder for infants of 12-36 months old, wherein the total protein content in the powdered formula is 13.0g/100g powder, and the fat content is 23.1g/100g powder; a carbohydrate content of 57.5g/100g flour; the content of the breast milk oligosaccharide composition is 0.1g/100g powder.
The infant formula powder is prepared by compounding the following raw materials in parts by weight:
1000 parts of raw milk, 225 parts of desalted whey powder, 225 parts of skimmed milk powder, 240 parts of lactose, 180 parts of mixed vegetable oil (containing OPO structural fat), 5 parts of whey protein powder, 1.1 parts of a breast milk oligosaccharide LNT and 3'-SL composition, wherein the mass ratio of the LNT to the 3' -SL is about 5:1, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process and mainly comprises the following components: proportioning, preheating, homogenizing, concentrating, sterilizing, spray drying, dry-mixing and adding breast milk oligosaccharide composition to obtain the final product.
Experimental results of improving intestinal leakage of Breast milk oligosaccharide
1. Experiments to improve paracellular permeability
The experiment examines the influence of different HMO and the composition thereof on the epithelial function of the small intestine under normal conditions, and the intestinal permeability and the intestinal barrier (improving paracellular permeability) among cells are improved through the indexes such as intestinal barrier, FD4 (fluorescein isothiocyanate dextran; FITC labeled dextran) molecular transport condition and the like.
Normal (non-invasive) conditions
Caco-2 cells were cultured in DMEM medium of transwell system for 21 days to simulate the small intestine epithelial cell layer. The test HMO or HMO composition (final concentration in the culture system 0.1 mg/mL) was added and cultured for 24 hours, followed by addition of FD4 molecules (final surface concentration 250 ug/mL) and further culture. FD4 molecule transport was measured at 24 hours of continued culture, and three times as biological replicates. A control group of DMEM medium without any HMO or HMO composition tested was also provided.
Data analysis
Statistical analysis of the molecular transport permeability data of FD4 was performed with two-tailed paired T-test. If there is a significant difference between the two groups, and p <0.05, the two groups are denoted by asterisks. Two asterisks indicate p <0.01. Three asterisks indicate p <0.001.
Experimental results
The results are shown in FIG. 1. For most HMO and HMO composition test groups, FD4 transport was closer to DMEM control. Whereas the mass ratio of the invention is 4:1 and 3'-SL significantly reduced FD4 molecular transport (P < 0.05), indicating that the LNT and 3' -SL compositions of the present invention improve intercellular intestinal permeability (decrease intercellular intestinal permeability), promote intestinal barrier, and analyze the effects mainly due to reduced intercellular gaps, improved intercellular tightness, and thus increased tightness of paracellular transport pathways, and effectively reduced intestinal leakage.
Tcda challenge experiments
The experiment examines the influence of HMO compositions with different proportions (the mass ratio of LNT to 3' -SL is 2:1 and 4:1 respectively) on the epithelial function of small intestine under the invasion condition of microbial toxin clostridium difficile toxin A (Clostridium difficile toxin A, tcDA), and the trans-membrane resistance TEER index is measured through the TcDA invasion experiment.
Caco-2 cells were cultured in DMEM medium of transwell system for 21 days to simulate the small intestine epithelial cell layer. The HMO composition to be tested (final concentration in the culture system 0.1 mg/mL) was added and cultured for 24 hours, then TcDA (final surface concentration 200 ug/mL) was added and the culture continued. The transmembrane resistance TEER was measured at 0, 3 hours after addition of TcDA for further culture, and three times as biological replicates. A control group of DMEM medium without any HMO or HMO composition tested was also provided.
Data analysis
For data of transmembrane resistance TEER, statistical analysis was performed using Tukey's multiple comparison test. If there is a significant difference between the two groups, and p <0.05, the two groups are denoted by asterisks. Two asterisks indicate p <0.01. Three asterisks indicate p <0.001.
Experimental results
Table 1 shows the effect of measuring transmembrane resistance after three hours of incubation with toxin A, LNT and 3' -SL compositions on transmembrane resistance.
TABLE 1
As can be seen from the results of the intestinal barrier test for three hours, the mass ratio was 2: the lnt+3' -SL composition of 1 significantly reduced the transmembrane resistance compared to the control, whereas the mass ratio of the present invention is 4: the lnt+3'-SL composition of 1 did not significantly reduce the transmembrane resistance, and demonstrated a trend of synergistic effect between the LNT and 3' -SL compositions of the specific ratio range of the present invention.
Claims (10)
1. The application of the formula milk powder in preparing a product with the effect of preventing intestinal leakage, wherein the formula milk powder contains the breast milk oligosaccharide lactose-N-tetraose and 3'-sialyllactose, and the mass ratio of the lactose-N-tetraose to the 3' -sialyllactose is (3-5): 1 and the total content of lactose-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g based on the total mass of the formula; wherein the lactose-N-tetraose alone in combination with 3' -sialyllactose as active ingredient prevents intestinal leakage; the preventing intestinal leakage includes improving intercellular intestinal permeability and/or intestinal barrier.
2. The use according to claim 1, wherein the total protein content is 10 g-20 g/100g and the fat content is 15-30 g/100g based on the total mass of the formula; the carbohydrate content is 50-70 g/100g.
3. The use according to claim 2, wherein the formula further comprises linoleic acid and alpha-linolenic acid, the linoleic acid content is 2700-4500 mg/100g, and the alpha-linolenic acid content is 270-450 mg/100g based on the total mass of the formula.
4. The use according to claim 1, wherein the formula is a formula for infants from 0 to 6 months, wherein the total protein content is 10 to 15g/100g, the fat content is 23 to 30g/100g, the linoleic acid content is 2700 to 4500 g/100g, the alpha-linolenic acid content is 270 to 450mg/100g, and the carbohydrate content is 50 to 60g/100g, based on the total mass of the formula.
5. The use according to claim 1, wherein the formula is for a older infant of 6-12 months, wherein the total protein content is 10-20 g/100g, the fat content is 20-30 g/100g, the linoleic acid content is 2700-4500 g/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-65 g/100g, based on the total mass of the formula.
6. The use according to claim 1, wherein the formula is a formula for infants between 12 and 36 months, wherein the total protein content is 10-20 g/100g, the fat content is 15-30 g/100g, the linoleic acid content is 2700-4500 g/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-70 g/100g, based on the total mass of the formula.
7. The use according to any one of claims 1 to 6, wherein the lactose-N-tetraose is used in an amount of 70.9-1515.3mg/100g of the formula based on the total mass of the formula.
8. The use according to claim 7, wherein lactose-N-tetraose is used in an amount of 70.9-757.7mg/100g of the formula based on the total mass of the formula.
9. The use according to any one of claims 1 to 6, wherein the formula further comprises one or more of dietary fiber, inositol, taurine, l-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, lactoferrin.
10. The use according to claim 1, wherein the formula is prepared according to the following method:
the milk oligosaccharide lactose-N-tetrasugar and 3' -sialyllactose are mixed with other raw materials in the formula milk powder by adopting a wet or dry production process to prepare the formula milk powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111453114.8A CN114145354B (en) | 2021-11-30 | 2021-11-30 | Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111453114.8A CN114145354B (en) | 2021-11-30 | 2021-11-30 | Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114145354A CN114145354A (en) | 2022-03-08 |
| CN114145354B true CN114145354B (en) | 2023-08-22 |
Family
ID=80455547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111453114.8A Active CN114145354B (en) | 2021-11-30 | 2021-11-30 | Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114145354B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024105129A1 (en) * | 2022-11-17 | 2024-05-23 | N.V. Nutricia | Compositions for reducing oxidative stress |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103501638A (en) * | 2010-12-31 | 2014-01-08 | 雅培制药有限公司 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
| CN107106584A (en) * | 2014-12-08 | 2017-08-29 | 格礼卡姆股份公司 | Synthetic composition for treating dysbolism |
| CN110506793A (en) * | 2019-09-23 | 2019-11-29 | 石家庄君乐宝乳业有限公司 | Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof |
| CN112514997A (en) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof |
| CN112535218A (en) * | 2020-12-08 | 2021-03-23 | 石家庄君乐宝乳业有限公司 | Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| CN113163833A (en) * | 2018-12-21 | 2021-07-23 | 雀巢产品有限公司 | Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180333426A1 (en) * | 2017-05-17 | 2018-11-22 | Mead Johnson Nutrition Company | Nutritional composition with human milk oligosaccharides and uses thereof |
-
2021
- 2021-11-30 CN CN202111453114.8A patent/CN114145354B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103501638A (en) * | 2010-12-31 | 2014-01-08 | 雅培制药有限公司 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| CN107106584A (en) * | 2014-12-08 | 2017-08-29 | 格礼卡姆股份公司 | Synthetic composition for treating dysbolism |
| CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
| CN113163833A (en) * | 2018-12-21 | 2021-07-23 | 雀巢产品有限公司 | Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function |
| CN110506793A (en) * | 2019-09-23 | 2019-11-29 | 石家庄君乐宝乳业有限公司 | Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| CN112514997A (en) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof |
| CN112535218A (en) * | 2020-12-08 | 2021-03-23 | 石家庄君乐宝乳业有限公司 | Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114145354A (en) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2607457C2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula, containing soluble oligosaccharide fraction present in milk, and having low level of monosaccharides, and process to produce composition | |
| JP4793533B2 (en) | Stimulation of the immune system with polydextrose | |
| CZ2003535A3 (en) | Foodstuff preparation | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| Seki et al. | Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men | |
| MX2015003660A (en) | Nutritional compositions including calcium beta-hydroxy-beta-meth ylbutyrate, protein and low levels of electrolytes. | |
| AU2019291666B2 (en) | Use of polar lipids to treat or prevent gestational diabetes mellitus | |
| CN114128767B (en) | Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides | |
| CN114145354B (en) | Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN116076728B (en) | Composition for promoting growth of bifidobacteria | |
| CN114145353A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114208893A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| US20210236528A1 (en) | Composition comprising isomers of inositol and its use | |
| CN114271340A (en) | Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof | |
| CN114451453B (en) | Breast milk oligosaccharide composition for preventing intestinal leakage and application thereof | |
| US20220400729A1 (en) | Synergistic combination of butyric-acid-producing prebiotics and probiotics | |
| CN114568527A (en) | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof | |
| JPH1029945A (en) | Enteric metabolism-improving agent | |
| WO2024223939A1 (en) | Compositions and methods for improving immune health | |
| WO2024223940A1 (en) | Compositions and methods for improving metabolic health | |
| KR100266799B1 (en) | Nutritional formula for patients with renal disease and process for preparing the same | |
| WO2024223938A1 (en) | Compositions and methods for improving brain health | |
| CN112384079A (en) | Nutritional composition for treating diarrhea, preparation and treatment method thereof | |
| CN115769840B (en) | Formula milk powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |